Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxin Dawaimixike Migao for insomnia with qi stagnation and blood stasis syndrome
ChiCTR2000029234Phase 4Not yet recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of yangxin dawaimixike migao in Insomnia (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoint: Insomnia Severity Index Scale (ISI). Planned start Jan 2020; status: not yet recruiting.
02
Drugs
yangxin dawaimixike migao
03
Conditions
Insomnia
Beyond the preview
Go deeper on ChiCTR2000029234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029234.